28 Oct 2015

Strong growth of core medicines – continued growth of the pipeline

Read More
23 Oct 2015

Acquisition of Own Shares (October 23, 2015)

Read More
16 Oct 2015

Acquisition of own shares (October 16, 2015)

Read More
15 Oct 2015

New Exploratory Analysis Showed Romosozumab Increased Estimated Bone Strength More Than Teriparatide

Read More
9 Oct 2015

Acquisition of own shares (October 9, 2015)

Read More
8 Oct 2015

UCB presenting data on osteoporosis and romosozumab at 2015 American Society for Bone and Mineral Research (ASBMR) Annual Meeting

Read More
8 Oct 2015

UCB with positive results for Vimpat® (lacosamide) in EU Phase 3 monotherapy study

Read More
4 Sep 2015

UCB’s strong presence at International Epilepsy Congress reinforces value to epilepsy patients

Read More
2 Sep 2015

UCB to sell its U.S. specialty generics business Kremers Urban to Lannett for US$ 1.23 billion in cash plus contingent payments

Read More
1 Sep 2015

UCB and Amgen announce positive top-line results from open-label study of romosozumab compared with Teriparatide

Read More
Subscribe to